OBJECTIVES: In synovial tissues of patients with rheumatoid arthritis (RA), strong expression of laminins and integrins co-localises with increased expression of inflammatory cytokines. Synovial fibroblasts (SF) contribute to the pathogenesis of RA through increased expression of cytokines and chemoattractant factors, one of which is interleukin-16 (IL16). A study was undertaken to investigate the regulatory pathways of IL16 in SF from patients with RA (RA-SF) and osteoarthritis (OA-SF). METHODS: SF were seeded in laminin-coated flasks and activated by the addition of cytokines. The expression of IL16 was investigated by quantitative RT-PCR, immunoblotting and ELISA; its biological activity was determined by a cell migration assay. Cell-matrix interactions were investigated by cell binding and attachment assays. Relevant intracellular signalling pathways were studied by immunoblotting and with pharmacological blocking reagents. RESULTS: Stimulation of SF with transforming growth factor beta(1)(TGF-beta(1)) and growth on laminin-111 (LM-111) significantly increased the expression of IL16. Binding to LM-111 induced significantly more IL16 mRNA in RA-SF than in OA-SF (p<0.05). The IL16 cytokine was detected in supernatants of TGF-beta(1)-activated and in LM-111+TGF-beta(1)-activated RA-SF (38 to 62 pg/ml), but not in supernatants of OA-SF. This IL16 regulation involved p38MAPK, ERK1/2 and SMAD2 signalling, but not NFkappaB. CONCLUSIONS: Binding of RA-SF to LM-111 in the presence of TGF-beta(1) triggers a significant IL16 response and thus may contribute to the infiltration of CD4+ lymphocytes into synovial tissues. This mode of IL16 induction represents a novel pathway leading to IL16 production in RA-SF but not in OA-SF, which operates independently of NFkappaB signalling.
OBJECTIVES: In synovial tissues of patients with rheumatoid arthritis (RA), strong expression of laminins and integrins co-localises with increased expression of inflammatory cytokines. Synovial fibroblasts (SF) contribute to the pathogenesis of RA through increased expression of cytokines and chemoattractant factors, one of which is interleukin-16 (IL16). A study was undertaken to investigate the regulatory pathways of IL16 in SF from patients with RA (RA-SF) and osteoarthritis (OA-SF). METHODS: SF were seeded in laminin-coated flasks and activated by the addition of cytokines. The expression of IL16 was investigated by quantitative RT-PCR, immunoblotting and ELISA; its biological activity was determined by a cell migration assay. Cell-matrix interactions were investigated by cell binding and attachment assays. Relevant intracellular signalling pathways were studied by immunoblotting and with pharmacological blocking reagents. RESULTS: Stimulation of SF with transforming growth factor beta(1)(TGF-beta(1)) and growth on laminin-111 (LM-111) significantly increased the expression of IL16. Binding to LM-111 induced significantly more IL16 mRNA in RA-SF than in OA-SF (p<0.05). The IL16 cytokine was detected in supernatants of TGF-beta(1)-activated and in LM-111+TGF-beta(1)-activated RA-SF (38 to 62 pg/ml), but not in supernatants of OA-SF. This IL16 regulation involved p38MAPK, ERK1/2 and SMAD2 signalling, but not NFkappaB. CONCLUSIONS: Binding of RA-SF to LM-111 in the presence of TGF-beta(1) triggers a significant IL16 response and thus may contribute to the infiltration of CD4+ lymphocytes into synovial tissues. This mode of IL16 induction represents a novel pathway leading to IL16 production in RA-SF but not in OA-SF, which operates independently of NFkappaB signalling.
Authors: Andrea Fava; Deepak A Rao; Chandra Mohan; Ting Zhang; Avi Rosenberg; Paride Fenaroli; H Michael Belmont; Peter Izmirly; Robert Clancy; Jose Monroy Trujillo; Derek Fine; Arnon Arazi; Celine C Berthier; Anne Davidson; Judith A James; Betty Diamond; Nir Hacohen; David Wofsy; Soumya Raychaudhuri; William Apruzzese; Jill Buyon; Michelle Petri Journal: Arthritis Rheumatol Date: 2022-04-16 Impact factor: 15.483
Authors: Carrie L Wagner; Sudha Visvanathan; Michael Elashoff; Iain B McInnes; Philip J Mease; Gerald G Krueger; Frederick T Murphy; Kim Papp; Juan J Gomez-Reino; Michael Mack; Anna Beutler; Dafna Gladman; Arthur Kavanaugh Journal: Ann Rheum Dis Date: 2012-09-12 Impact factor: 19.103
Authors: Sudha Visvanathan; Mahboob U Rahman; Edward Keystone; Mark Genovese; Lars Klareskog; Elizabeth Hsia; Michael Mack; Jacqui Buchanan; Michael Elashoff; Carrie Wagner Journal: Arthritis Res Ther Date: 2010-11-17 Impact factor: 5.156
Authors: Raquel E Reinbolt; Stephen Sonis; Cynthia D Timmers; Juan Luis Fernández-Martínez; Ana Cernea; Enrique J de Andrés-Galiana; Sepehr Hashemi; Karin Miller; Robert Pilarski; Maryam B Lustberg Journal: Cancer Med Date: 2017-11-23 Impact factor: 4.452